6-氟-2-碘苯甲酰胺 | 676445-27-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-氟-2-碘苯甲酰胺
• 中文别名: 2-碘-6-氟苯甲酰胺
• 英文名称: 6-fluoro-2-iodobenzamide
• 英文别名: 2-fluoro-6-iodobenzamide
• CAS: 676445-27-5
• 化学式: C₇H₅FINO
• 分子量: 265.026
• InChiKey: UYNQRXGMTNELSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  6-氟-2-碘苯甲酰胺 在 palladium diacetate 盐酸 、 potassium carbonate 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 14.5h， 生成 [(1R)-1-[2-fluoro-4-[3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]phenyl]ethyl]azanium;chloride
  参考文献：
  名称：

  Development of Orally Bioavailable and CNS Penetrant Biphenylaminocyclopropane Carboxamide Bradykinin B₁ Receptor Antagonists

  摘要：

  A series of biphenylaminocyclopropane carboxamide based bradykinin B-1 receptor antagonists has been developed that possesses good pharmacokinetic properties and is CNS penetrant. Discovery that the replacement of the trifluoropropionamide in the lead structure with polyhaloacetamides, particularly a trifluoroacetamide, significantly reduced P-glycoprotein mediated efflux for the series proved essential. One of these novel bradykinin B-1 antagonists (13b) also exhibited suitable pharmacokinetic properties and efficient ex vivo receptor occupancy for further development as a novel approach for the treatment of pain and inflammation.

  DOI：

  10.1021/jm061094b
• 作为产物：
  描述：

  2-氟-6-碘苯甲酰氯 在 氨 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 6-氟-2-碘苯甲酰胺
  参考文献：
  名称：

  Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents

  摘要：

  Agonists of the 5-HT2C receptor have been shown to suppress appetite and reduce body weight in animal models as well as in humans. However, agonism of the related 5-HT2B receptor has been associated with valvular heart disease. Synthesis and biological evaluation of a series of novel and highly selective dihydroquinazolinone-derived 5-HT2C agonists with no detectable agonism of the 5-HT2B receptor is described. Among these, compounds (+)-2a and (+)-3c were identified as potent and highly selective agonists which exhibited weight loss in a rat model upon oral dosing. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.014

文献信息

• 2-(biarylalkyl)amino-3-(fluoroalkanoylamino)pyridine derivatives
  申请人：——

  公开号：US20040063761A1

  公开（公告）日：2004-04-01

  Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

  本文披露的化合物是布雷金肽B1拮抗剂化合物，可用于治疗或预防与布雷金肽B1途径相关的疼痛和炎症症状。
• Electronic Control of Chiral Quaternary Center Creation in the Intramolecular Asymmetric Heck Reaction
  作者：Carl A. Busacca、Danja Grossbach、Scot J. Campbell、Yong Dong、Magnus C. Eriksson、Robert E. Harris、Paul-James Jones、Ji-Young Kim、Jon C. Lorenz、Keith B. McKellop、Erin M. O'Brien、Fenghe Qiu、Robert D. Simpson、Lana Smith、Regina C. So、Earl M. Spinelli、Jana Vitous、Chiara Zavattaro

  DOI：10.1021/jo049448z

  日期：2004.8.1

  The Boehringer-Ingelheim phosphinoimidazoline (BIPI) ligands were applied to the formation of chiral quaternary centers in the asymmetric Heck reaction. Several different substrates were examined in detail, using more than 70 members of this new ligand class. Hammett relationships were determined through systematic variation of the ligand electronics. All substrates showed essentially the same Hammett behavior, where enantioselectivity increased as the ligands were made more electron-deficient. Ligand optimization has led to catalysts which give the highest enantioselectivities reported to date for these difficult systems.
• METHOD FOR INHIBITING TRYPANOSOMA CRUZI
  申请人：Bakare Oladapo

  公开号：US20150073177A1

  公开（公告）日：2015-03-12

  Methods are provided to inhibit proliferation of Trypanosoma cruzi with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can be used to provide prophylaxis or treatment to a patient in need of treatment against Chagas disease.